Magazine Article | December 1, 2022

The Top Reasons Bioprocessing CDMOs Lose Bids

Source: Life Science Leader

By Industry Standard Research

Respondents continue to report that service providers primarily lose bids for bioprocessing efforts due to regulatory violations/FDA form 483 warnings (49%), their inability to meet required timelines (48%), and high cost (47%). Roughly one-fifth of this year’s survey participants listed regulatory violations and timeline shortcomings as the main reasons why a CDMO is not selected (23% and 19%, respectively).

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader